These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31547858)

  • 41. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
    Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
    Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Immunophenotype of Nodular Variant of Medullary Carcinoma of the Breast.
    Reyes C; Nadji M
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):624-7. PubMed ID: 25710588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
    Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
    Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of nuclear FOXP3 expression with low Ki67 index and better prognosis in patients with breast invasive ductal carcinoma.
    Li J; Zhang X; Zheng L; Liu Y
    Neoplasma; 2017; 64(5):754-761. PubMed ID: 28592128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
    Faratian D; Munro A; Twelves C; Bartlett JM
    Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
    Rehman S; Crow J; Revell PA
    Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [BRCA1- and BRCA2- associated breast carcinomas].
    Ahrens P; Kreipe HH
    Pathologe; 2009 Dec; 30 Suppl 2():207-9. PubMed ID: 19795125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer.
    Kolokytha P; Yiannou P; Keramopoulos D; Kolokythas A; Nonni A; Patsouris E; Pavlakis K
    Appl Immunohistochem Mol Morphol; 2014; 22(2):125-31. PubMed ID: 23702644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell proliferation in breast tumours: analysis of histological parameters Ki67 and PCNA expression.
    Sullivan RP; Mortimer G; Muircheartaigh IO
    Ir J Med Sci; 1993 Sep; 162(9):343-7. PubMed ID: 7903289
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
    van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
    Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
    Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
    Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients.
    Pacheco-Velázquez SC; Gallardo-Pérez JC; Aguilar-Ponce JL; Villarreal P; Ruiz-Godoy L; Pérez-Sánchez M; Marín-Hernández A; Ruiz-García E; Meneses-García A; Moreno-Sánchez R; Rodríguez-Enríquez S
    Int J Oncol; 2014 Dec; 45(6):2549-59. PubMed ID: 25270118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization.
    Nakagawa T; Horii R; Ito Y; Iwase T; Akiyama F
    Breast Cancer; 2016 Jan; 23(1):78-84. PubMed ID: 24771412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Breast cancer in young women. Histological and prognostic specificities: how are they different from older women?].
    Arnould L; Penault-Llorca F; Dohollou N; Caron O; Levy C
    Bull Cancer; 2019 Dec; 106(12S1):S10-S18. PubMed ID: 32008732
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes.
    Cotarelo CL; Schad A; Kirkpatrick CJ; Sleeman JP; Springer E; Schmidt M; Thaler S
    Oncotarget; 2016 Nov; 7(46):74846-74859. PubMed ID: 27713152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.